TEMRegulationbusinesswire

Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device

Sentiment:Positive (70)

Summary

(NASDAQ:TEM) CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporti

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 11, 2025 by businesswire